Canada Patent

Filing a patent in Canada is done through the Canadian Intellectual Property Office (CIPO), either directly or through PCT national phase entry within 30 months of the earliest priority date. Foreign applicants must use a Canadian Registered Patent Agent — a US patent attorney or agent cannot prosecute a Canadian patent application before CIPO without also being registered as a Canadian patent agent. Most US applicants work with a US patent firm that has a Canadian correspondent agent for Canadian prosecution. Direct filing fees: CA$266 base (large entity) or CA$133 (small entity), plus CA$22 per claim beyond 20. If you have a US application, the standard path is: (1) file a US provisional or non-provisional; (2) file a PCT application within 12 months of the US filing; (3) enter Canadian national phase within 30 months from the earliest priority date; (4) file a Request for Examination within 4 years of the Canadian filing date; (5) respond to CIPO Office Actions through a Canadian patent agent; (6) pay maintenance fees annually from year 2. Canada is a first-inventor-to-file country and aligns with the Patent Cooperation Treaty. The official language of prosecution is either English or French. Canadian patents are widely enforced — Canada has an active Federal Court that handles patent matters and provides injunctive relief. The patent term is 20 years from the Canadian national filing date.

In Canada, a Request for Examination must be filed within 4 years of the filing date for applications filed after October 30, 2019 (the Canada Patent Act amendment that changed the deadline from 5 years to 4 years). For applications filed before October 30, 2019, the deadline is 5 years from the filing date. If no Request for Examination is filed by the deadline, the application is deemed abandoned — and while revival may be possible, the process requires a petition and fees, and the abandonment may affect patent term. The examination request fee is CA$816 for large entities and CA$408 for small entities (approximately 50% discount). The 4-year window is a strategic buffer: applicants can evaluate whether the invention has commercial potential before committing the examination fees, prosecution costs, and ongoing attorney fees. This is particularly useful for early-stage startups that file broadly but may narrow their active prosecution focus as the business develops. Unlike Japan (3-year window) and some other jurisdictions, Canada's 4-year window is one of the longer examination request periods among major patent offices, giving applicants substantial flexibility in timing prosecution investment.

The 'promise of the patent' doctrine was a Canadian patent law requirement developed over decades of case law holding that a patent must fulfill all utilities 'promised' in the specification — and if the patent promised a specific level of utility (e.g., 'effective for treating disease X') but could not demonstrate that utility at the time of filing, the patent was invalid for insufficient utility. The doctrine was particularly problematic for pharmaceutical patents, because drug developers often described broad therapeutic potential in their specifications without yet having all clinical data to support every stated utility. This led to a series of decisions invalidating pharmaceutical patents on the grounds that the specification had 'promised' more utility than could be soundly predicted at the filing date. The Supreme Court of Canada abolished the promise doctrine in AstraZeneca Canada Inc. v. Apotex Inc. [2017] SCC 36. AstraZeneca's patent on esomeprazole (Nexium) had been invalidated under the promise doctrine. The Supreme Court held that the promise doctrine was inconsistent with proper statutory construction of the Patent Act's utility requirement — the Act requires only that an invention be 'useful,' not that it fulfill every statement of advantage in the specification. Post-AstraZeneca, Canadian utility law now requires only that the patent cover something useful — the same basic 'specific, substantial, credible utility' analysis. Statements of advantage in the specification are no longer read as promises. This change substantially improved Canada's attractiveness for pharmaceutical patent protection and brought Canada's utility standard more in line with international norms.

Canadian patent law does not have a formal Alice/Mayo § 101 framework for software and business method eligibility. Canada's Patent Act requires that an invention be a 'useful art' to be patentable — which Canada's courts have interpreted to require that the invention have a physical existence or manifestation, or produce a discernible physical effect or change. CIPO's Examination Practice Respecting Computer-Implemented Inventions (most recently updated in guidance) requires examiners to assess the claim as a whole — not just the result — to determine whether it is directed to a physical object or a physical effect. In practice: (1) Software claims tied to a specific technical effect (improving computer performance, a specific algorithm that processes sensor data to produce a physical output) are often allowable in Canada; (2) Pure mathematical algorithms or business methods with no discernible technical effect remain difficult to patent; (3) Canada has not had a Supreme Court decision directly addressing software eligibility equivalent to Alice — making Canadian software patent law less predictable than US law but also avoiding the most aggressive § 101 rejections common at the USPTO. The Federal Court has addressed eligibility in specific cases but the landscape remains more permissive than post-Alice US practice for many software inventions. For US applicants: Canadian claims that face § 101 rejections in the US often fare better at CIPO because Canada does not apply the Alice two-step test, and claims directed to an improvement in computer operation or a specific technical effect are examined more favorably.

As of 2026, Canada does NOT have a patent term extension (PTE) equivalent to the US Hatch-Waxman PTE under 35 U.S.C. § 156 or the EU Supplementary Protection Certificate (SPC). Canadian pharmaceutical patents expire at 20 years from the filing date with no extension for regulatory delays — regardless of how long the drug spent in clinical trials and regulatory review before receiving Health Canada approval. Data protection (data exclusivity) provides some relief: innovative pharmaceutical manufacturers receive 8 years of data exclusivity on clinical data submitted to Health Canada, plus a potential 6-month extension for pediatric clinical studies — but this is data exclusivity, not patent term extension, and it operates independently of patent term. For pharmaceutical companies: the absence of Canadian PTE is a significant competitive disadvantage compared to the US and EU systems, where PTE can add up to 5 years to a drug patent's term. Companies with innovative drugs should factor in the shorter effective exclusivity period in Canada when planning their Canadian patent and regulatory strategies. Canadian courts have consistently applied the 20-year cap. Legislative proposals to introduce a form of certificate of supplementary protection were advanced in conjunction with CETA (the Comprehensive Economic and Trade Agreement between Canada and the EU), and a certificate of supplementary protection system was established under CETA implementation (Bill C-30, 2017) — however, the specific terms, limitations, and scope of Canada's certificate of supplementary protection differ from the US PTE and EU SPC systems. Consult a Canadian patent agent for current details on the certificate of supplementary protection as it applies to specific pharmaceutical products.